• Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z, Issa H, Cheng B, Abu Raddad LJ, Buckeridge DL, Van Kerkhove MD, Piechotta V, Higdon MM, Wilder-Smith A, Bergeri I, Feikin DR, Arora RK, Patel MK, Subissi L., 2023. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556-567.

  • Boppana S, Qin K, Files JK, Russell RM, Stoltz R, Bibollet-Ruche F, Bansal A, Erdmann N, Hahn BH, Goepfert PA, 2021. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathog. 17, e1009761.

  • Chemaitelly H, Tang P, Coyle P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Ayoub HH, Altarawneh HN, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ; National Study Group for COVID-19 Epidemiology., 2023. Protection against reinfection with the omicron BA.2.75 subvariant. N. Engl. J. Med. 388, 665-667.

  • Gong F, Dai Y, Zheng T, Cheng L, Zhao D, Wang H, Liu M, Pei H, Jin T, Yu D, Zhou P., (2020. Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. J. Clin. Investig. 130, 6588-6599.

  • Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211.

  • Ma X, Zou F, Yu F, Li R, Yuan Y, Zhang Y, Zhang X, Deng J, Chen T, Song Z, Qiao Y, Zhan Y, Liu J, Zhang J, Zhang X, Peng Z, Li Y, Lin Y, Liang L, Wang G, Chen Y, Chen Q, Pan T, He X, Zhang H., 2020. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315-1330.e1319.

  • Narowski TM, Raphel K, Adams LE, Huang J, Vielot NA, Jadi R, de Silva AM, Baric RS, Lafleur JE, Premkumar L., 2022. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Rep. 38, 110336.

  • Yu D, Walker LSK, Liu Z, Linterman MA, Li Z., 2022. Targeting TFH cells in human diseases and vaccination: rationale and practice. Nat. Immunol. 23, 1157-1168.

  • Yu M, Charles A, Cagigi A, Christ W, Osterberg B, Falck-Jones S, Azizmohammadi L, Ahlberg E, Falck-Jones R, Svensson J, Nie M, Warnqvist A, Hellgren F, Lenart K, Arcoverde Cerveira R, Ols S, Lindgren G, Lin A, Maecker H, Bell M, Johansson N, Albert J, Sundling C, Czarnewski P, Klingstrom J, Farnert A, Lore K, Smed-Sorensen A., 2023. Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19. Nat. Commun. 14, 2164.

  • Zhang J, Wu Q, Liu Z, Wang Q, Wu J, Hu Y, Bai T, Xie T, Huang M, Wu T, Peng D, Huang W, Jin K, Niu L, Guo W, Luo D, Lei D, Wu Z, Li G, Huang R, Lin Y, Xie X, He S, Deng Y, Liu J, Li W, Lu Z, Chen H, Zeng T, Luo Q, Li YP, Wang Y, Liu W, Qu X, 2021. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat Microbiol 6, 51-58.

  • Zhang Y, Li R, Li Y, Yang H, Zhou L, Yuan J, Pan T, Liu B, Zhang H, He Y., 2023. Antibody response and cross-neutralization after Omicron BA.2 infection. Signal Transduct. Target Ther. 8, 25.